Contraceptive Drugs Market Overview, COVID-19 impact, segment review, End-user, Top Companies Analysis - 2027

Rise in usage of oral contraceptives as a preferred method to avoid unplanned pregnancy drive the growth of the global contraceptive drugs market.

Global Contraceptive Drugs Market was pegged at $14.32 billion in 2019, and is anticipated to garner $24.42 billion by 2027, manifesting a CAGR of 6.9% from 2020 to 2027. The report provides detailed analysis of changing market dynamics, top segments, value chain, key investment pockets, competitive scenario, and regional landscape.

Growth in need to prevent unwanted pregnancy, surge in awareness for contraceptives across the world, and rise in usage of oral contraceptives as a preferred method to avoid unplanned pregnancy drive the growth of the global contraceptive drugs market. By region, the market across North America dominated in 2019, and would lead the trail throughout the forecast period.

Download Sample Report at:

Covid-19 scenario-

During the outbreak of the pandemic the contraceptive drug manufacturers have been through several challenges with unpredictable and distorted supply chain activities and lack of skillful human resources. Also, declined number of hospital visits by women to receive injectable further affected the market.

However, as the restrictions are getting eased off, the global market for contraceptive drugs is expected to recoup soon.

The global market is segmented on the basis of product, age group, end-user, and region. Based on product, the oral contraceptive pills segment held the lion’s share with more than four-fifths of the global contraceptive drugs market share in 2019, and is expected to dominate by the end of 2027. However, the injectable contraceptives segment is expected to manifest the fastest CAGR of 8.0% throughout the forecast period.

The growth of the global contraceptive drugs market is driven by alarming increase in the incidence of STDs, rise in unintended pregnancy rate, and need for family planning across the world, owing to rapidly growing population and socioeconomic burden related to teenage pregnancy. The impact of the drivers is expected to surpass that of the restraints.

On the basis of end user, the market is classified into homecare, hospitals, and clinics. The homecare segment garnered the largest share in the global contraceptive market, owing to the extensive consumption of oral pills to prevent unplanned pregnancy and STIs. Contraceptives that are favored in home settings comprise oral pills, topical contraceptives, and contraceptive patches. These contraceptives help to reduce the risk of pregnancy and chance of getting STIs. Increase in use of contraceptive drugs at home has improved health-related outcomes such as maternal & infant mortality; reduced the risk of STI such as HIV, hepatitis B, syphilis, and gonorrhea; and improved economic outcomes of a family.

Enquiry for Short-term and Long-term Impacts of COVID-19 at:

Based on age group, the 15-24 years segment dominated the market with more than half of the global contraceptive drugs market revenue in 2019, and is anticipated to rule the roost by 2027. On the other hand, the above 44 years segment would exhibit the fastest CAGR of 9.0% during the forecast period.

The key players profiled in this report include Agile Therapeutics, Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson, Piramal Healthcare, Mylan N.V., Pfizer Inc., Novartis AG and Teva Pharmaceutical Industries Ltd. Other players operating in the market are HLL Lifecare ltd, and Sanofi.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying:

Contact Info:
Name: David Correa
Email: Send Email
Organization: Allied Market Research

Release ID: 89033883